Jeffrey T. Yap

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Lalitha Shankar, John M. Hoffman, S.L. Bacharach et al. · PubMed · 2006 · 679 citations

Medicine, Nuclear Medicine, Oncology +17

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Conan G. Kinsey, Soledad A. Camolotto, Amélie Boespflug et al. · Nature Medicine · 2019 · 648 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Donald P. Lawrence, Cecilia Lezcano et al. · Cancer Immunology Research · 2014 · 604 citations · Full text

Pharmacy, Immunology, Pharmacology +16

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder et al. · Journal of Clinical Oncology · 2013 · 595 citations · Full text

Medicine, Dermatology, Oncology +17

PET/CT today and tomorrow.

David W. Townsend, Jonathan Carney, Jeffrey T. Yap et al. · PubMed · 2004 · 394 citations

Medicine, Anatomy, Radiology +17